INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment the

Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ i

Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ i

INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript

INmune Bio NASDAQ: INMB outlined plans to file for conditional approval of its Ebstrocel cell therap

BOCA RATON, Fla. , July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"),

Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2

Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development

Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Re

Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Re

The Department of Defense–funded study; entitled: "Inhibition of Soluble TNF Mitigates Traumatic

The study points to soluble TNF as a key biological link between head injury and Alzheimer's disease

Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and co

Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and co

Submission advances a key element of the Company’s global intellectual property strategy for its nex

Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Prog

INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on

Approval of pediatric strategy validates clinical data package and accelerates the regulatory path f

MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions co

MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions co

XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46;

XPro1595 showed a highly significant treatment effect in the full mITT population (p=0. 0028; d=0. 4

Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage bi

INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.20) per share which beat the analyst conse

https://www.businessinsider.com/short-squeeze-stock-market-meme-stocks-retail-investors-25-8

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quart

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss a

Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at

Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i

  Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua